The first patient, affected by HR+/HER2- breast cancer, suffered from a metastatic tumor recurrence on adjuvant endocrine therapy, for which she received a tumor sequencing revealing a clonal CDK6 R46Q variant, together with a mono-allelic FAT1 mutation without annotated functional significance (variance of unknown significance). The gene discussed is ERBB2; the disease is metastatic neoplasm.